REGENERON PHARMACEUTICALS INC Form SC 13D/A March 22, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO 8) *

REGENERON PHARMACEUTICALS, INC. (Name of Issuer)

COMMON STOCK, \$.001 PAR VALUE (Title of Class of Securities)

00075886F1 (CUSIP Number)

Steven M. Odre, Esq.
Senior Vice President,
General Counsel and Secretary
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
(808) 447-1000

with a copy to:
Gary Olson, Esq.
Latham & Watkins
633 West Fifth Street
Suite 4000
Los Angeles, California 90071
(213) 485-1234

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 19, 2001 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. [_]

Check the following box if a fee is being paid with the statement. [_] (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)


NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. SEE Rule 13d-1(a) for other parties to whom copies are to be sent

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP	IP No. 00075886F1		
1	NAME OF PERSON		
	AMGEN INC.		
2	CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP* (a) [_] (b) [_]		
3	SEC USE ONLY		
4	SOURCE OF FUNDS*		
	N/A		
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_]		
6	CITIZENSHIP OR PLACE OF ORGANIZATION		
	DELAWARE		
		7	SOLE VOTING POWER
	NUMBER OF SHARES -	/	4.016.000
			4,916,808
BE	NEFICIALLY	8	SHARED VOTING POWER
	OWNED BY		N/A
	EACH		SOLE DISPOSITIVE POWER
R	EPORTING	9	
	PERSON		4,916,808
	WITH	10	SHARED DISPOSITIVE POWER
			N/A
11	AGGREGATE AI	MOUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON
	4,916,808		
12	CHECK BOX I		GREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES



This Amendment No. 8 to Schedule 13D is being filed by Amgen Inc., a Delaware corporation (the "Reporting Person"), to amend the Schedule 13D filed on July 26, 1995, as amended by Amendment No. 1 filed on September 25, 1995, Amendment No. 2 filed on December 6, 1995, Amendment No. 3 filed on March 5, 1996, Amendment No. 4 filed on April 18, 1996, Amendment No. 5 filed on March 7, 2000, Amendment No. 6 filed on April 5, 2000 and Amendment No. 7 filed on March 13, 2001 ("Schedule 13D"), relating to the common stock, \$.001 par value per share (the "Common Stock") of Regeneron Pharmaceuticals, Inc. (the "Issuer"). Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the meaning assigned to them in the Schedule 13D.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Item 6 to Schedule 13D is hereby amended and supplemented to add the following:

On March 19, 2001, the Reporting Person, the Issuer and Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc. and Robertson Stephens, Inc. (collectively, the "Underwriters"), entered into a Purchase Agreement (the "Purchase Agreement") which provides for (i) the issue and sale by the Issuer and the sale by the Reporting Person, acting severally and not jointly, and the purchase by the Underwriters, acting severally and not jointly, of 7,000,000 shares of Common Stock at a price of \$23.75 per share and (ii) the grant by the Issuer to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) thereof to purchase all or any part of 1,050,000 additional shares of Common Stock to cover over-allotments, if any.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Item 7 to Schedule 13D is hereby amended and supplemented as follows:

7.11 Purchase Agreement, dated March 19, 2001, by and among the Issuer, the Reporting Person, Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc. and Robertson Stephens, Inc.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, ${\tt I}$ certify that the information set forth in this statement is true, complete and correct.

AMGEN INC.

By: /s/ Kurt A. Gustafson

Name: Kurt A. Gustafson

Title: Vice President, Financial Planning and Analysis

Dated: March 21, 2001